Grifols sees 2025 revenue EUR 7.7B, EBITDA above EUR 2B

The company said, “Building on the solid performance of 2024, Grifols (GRFS) forecasts continued success in 2025 with anticipated revenue growth and EBITDA expansion. Excluding the impact of the Part D redesign within the U.S. Inflation Reduction Act (IRA), the company expects revenue of EUR 7.7 billion, reflecting a 7% growth rate, driven primarily by strong demand from its Biopharma division, particularly for key proteins. Grifols further projects that EBITDA will exceed EUR 2 billion, marking an increase of approximately 14% year-over-year. free cash flow is expected to reach EUR 500 million. The impacts from the Part D redesign of the IRA, estimated to range between EUR 100 to EUR 150 million, bring Grifols’ anticipated revenue to approximately EUR 7.6 billion, adjusted EBITDA to approximately EUR 1.85-1.9 billion, and free cash flow pre-M&A to a range of EUR 350-400 million.”